Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CAPRBullishIndustry Newsnews

High materiality7/10

Capricor CAPR: PDUFA extended; HOPE-3 data strengthen upper-limb indication

Aug 24, 2026, 9:30 AM EDT3 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The extended PDUFA date coupled with strengthened HOPE-3 data raises the probability of a favorable regulatory outcome or label refinement, which historically can drive a positive re-rating for CAPR; however, actual approval remains contingent on FDA judgment and timing.

AI summary

What happened, with direct paths to the underlying reporting

Capricor reported that the FDA extended the PDUFA target date for Deramiocel to November 22, 2026 after submitting a major amendment with 24-month HOPE-3 data aimed at a refined upper-limb indication. HOPE-3 met its primary endpoint, strengthening evidence that Deramiocel can preserve upper limb function in Duchenne patients, potentially expanding the label and value drivers for CAPR.

FDA extends Deramiocel PDUFA date to Nov 22, 2026.
Amendment includes 24-month HOPE-3 data supporting a refined indication.
HOPE-3 met primary endpoint for upper-limb function.
FDA classifies amendment as major; review window extended.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.